Loading...
Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States and carries a very poor prognosis, with a median survival time of <50% at 1 year for advanced disease. To date, sorafenib is the only therapy approved by the Food and Drug Administration for th...
Na minha lista:
| Udgivet i: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5118026/ https://ncbi.nlm.nih.gov/pubmed/27896243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S106072 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|